Evidence map›Paper›PMID 40800505›Full record

ArticleImaging neuroscience (Cambridge, Mass.)2024

Regional deep atrophy: Using temporal information to automatically identify regions associated with Alzheimer's disease progression from longitudinal MRI.

Mengjin Dong, Long Xie, Sandhitsu R Das, Jiancong Wang, Laura E M Wisse, Robin deFlores, David A Wolk, Paul A Yushkevich

Abstract read
In one paragraph

Article in Imaging neuroscience (Cambridge, Mass.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mengjin DongUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Long XieSiemens Healthineers, Malvern, PA, United States.
Sandhitsu R DasUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Jiancong WangUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Laura E M WisseLund University, Lund, Sweden.
Robin deFloresInstitut National de la Santé et de la Recherche Médicale (INSERM), Caen, France.
David A WolkUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Paul A YushkevichUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
A harmonized medial temporal lobe subregion segmentation protocol: an essential element for dementia researchR01AG070592 · NIA · WAYNE STATE UNIVERSITY · PI Ana Marie Daugherty, Rosanna Kathleen Olsen · 2022 to 2026
$3.5M
Modulators of Medial Temporal Lobe Subregion Structure and Function in Normal and Pathological AgingR01AG055005 · NIA · UNIVERSITY OF PENNSYLVANIA · PI WOLK, DAVID A · 2017 to 2021
$3.3M
Ex Vivo Imaging of the Aging Brain to Discover Morphology/Pathology AssociationsRF1AG056014 · NIA · UNIVERSITY OF PENNSYLVANIA · PI YUSHKEVICH, PAUL A. · 2023 to 2023
$2.1M
Optimized Arterial Spin Labeling MRI in Mild Cognitive ImpairmentR01AG040271 · NIA · UNIVERSITY OF PENNSYLVANIA · PI WOLK, DAVID A · 2012 to 2016
$2.0M
Improving the sensitivity and specificity of MRI-based biomarkers in Alzheimer's diseaseR01AG069474 · NIA · UNIVERSITY OF PENNSYLVANIA · PI WOLK, DAVID A, YUSHKEVICH, PAUL A. · 2024 to 2025
$1.4M
NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG040271NIA NIH HHS R01 AG055005NIA NIH HHS R01 AG069474NIA NIH HHS R01 AG070592NIA NIH HHS RF1 AG056014NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Longitudinal assessment of brain atrophy, particularly in the hippocampus, is a well-studied biomarker for neurodegenerative diseases, such as Alzheimer's disease (AD). Estimating brain progression patterns can be applied to understanding the therapeutic effects of amyloid-clearing drugs in research and detecting the earliest sign of accelerated atrophy in clinical settings. However, most state-of-the-art measurements calculate changes directly by segmentation and/or deformable registration of MRI images, and may misreport head motion or MRI artifacts as neurodegeneration, impacting their accuracy. In our previous study, we developed a deep learning method DeepAtrophy that uses a convolutional neural network to quantify differences between longitudinal MRI scan pairs that are associated with time. DeepAtrophy has high accuracy in inferring temporal information from longitudinal MRI scans, such as temporal order or relative interscan interval. DeepAtrophy also provides an overall atrophy score that was shown to perform well as a potential biomarker of disease progression and treatment efficacy. However, DeepAtrophy is not interpretable, and it is unclear what changes in the MRI contribute to progression measurements. In this paper, we propose Regional Deep Atrophy (RDA), which combines the temporal inference approach from DeepAtrophy with a deformable registration neural network and attention mechanism that highlights regions in the MRI image where longitudinal changes are contributing to temporal inference. RDA has similar prediction accuracy as DeepAtrophy, but its additional interpretability makes it more acceptable for use in clinical settings, and may lead to more sensitive biomarkers for disease monitoring and progression understanding in preclinical AD.

Indexed as

Alzheimer’s diseaseattention mapslongitudinal analysismedial temporal lobesensitive biomarkersstructural MRI

Identifiers

PMID40800505
PMCPMC12290704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.